Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 9/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SORD | Q00796 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23015683 | 0.86 | TRPV3 (0.38) | TRPV3ADRA2C | |
| SCHEMBL23015777 | 0.77 | TRPV3 (0.39) | TRPV3ADRA2CMAP4K4TRPV1 | |
| SCHEMBL830187 | 0.77 | CYP1A2 (0.37) | MAP4K4CYP1A2POLBSORD | |
| Ammonia Solution, Strong SCHEMBL28652832 | 0.75 | CYP1A2 (0.36) | MAP4K4CYP1A2POLB | |
| Ammonia Solution, Strong SCHEMBL11451734 | 0.74 | CYP1A2 (0.35) | MAP4K4CYP1A2POLB | |
| SCHEMBL12380171 | 0.73 | HRH1 (0.39) | TRPV3ADRA2CMAP4K4TRPV1 | |
| SCHEMBL28160853 | 0.72 | CYP1A2 (0.38) | MAP4K4CYP1A2POLB | |
| SCHEMBL16248159 | 0.72 | KDM4E (0.37) | MAP4K4CYP1A2POLB | |
| SCHEMBL25987002 | 0.72 | SORD (0.47) | CYP1A2POLBSORD | |
| SCHEMBL28806573 | 0.72 | MAP4K4 (0.35) | MAP4K4CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | PHARMASUM THERAPEUTICS AS (NO) | 2021-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | DYRK1A, DYRK1B, PDK2 | TRPV3 3145/4885ADRA2C 2604/4885MAP4K4 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.